FDA Approves New Sweetener, Advantame

Statement of CSPI Senior Scientist Lisa Lefferts


CSPI will be carefully reviewing the studies onĀ Advantame.

However, an initial concern is that in a key cancer study in mice, the number of mice that survived to the end of the study was below FDA's own scientific recommendations, and is therefore inadequate to provide confidence in the safety of a chemical likely to be consumed by millions of people.

Related Links and Downloads: